13.25
-2.14(-13.91%)
Currency In USD
| Previous Close | 15.39 |
| Open | 14.68 |
| Day High | 15.03 |
| Day Low | 12.41 |
| 52-Week High | 597.6 |
| 52-Week Low | 3.08 |
| Volume | 248,058 |
| Average Volume | 1.86M |
| Market Cap | 20.99M |
| PE | 0.31 |
| EPS | 43.2 |
| Moving Average 50 Days | 11.8 |
| Moving Average 200 Days | 74.31 |
| Change | -2.14 |
If you invested $1000 in Cyclacel Pharmaceuticals, Inc. (CYCC) 10 years ago, it would be worth $0.02 as of July 30, 2025 at a share price of $13.25. Whereas If you bought $1000 worth of Cyclacel Pharmaceuticals, Inc. (CYCC) shares 5 years ago, it would be worth $0.8 as of July 30, 2025 at a share price of $13.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY
GlobeNewswire Inc.
Jul 16, 2025 1:00 PM GMT
Kuala Lumpur, Malaysia, July 16, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today commented on recent stock price
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
GlobeNewswire Inc.
Jul 07, 2025 10:00 AM GMT
Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it has entered in
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
GlobeNewswire Inc.
Jul 07, 2025 10:00 AM GMT
- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, N